Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NCT05408845Phase 2Recruiting
- Sponsor
- NRG Oncology
- Start
- Mar 2023
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine, trastuzumab deruxtecan in salivary gland cancer (SGC), sponsored by NRG Oncology. Started Mar 2023; status: recruiting.
02
Drugs
trastuzumab emtansinetrastuzumab deruxtecan
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT05408845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408845.